Updates in the Treatment of Vitiligo

September 1st 2022

Dr David Rosmarin, MD, explores the treatment landscape and clinical burden associated with vitiligo.

Unbranded Biologics: An Overview

August 10th 2022

A discussion series reviewing the differences between unbranded biologics and biosimilars and an overview of payer and provider considerations for decision-making.

Examining Evolving Treatment Paradigms in the Hemophilia B Space

August 10th 2022

This content is a production of Managed Healthcare Executive; distribution of this K-Cast is supported by funding from CSL Behring LLC. CSL Behring LLC was not involved in the creation of the content of this production.

Steven Pipe, MD, discusses the treatment options for patients with hemophilia B, including his hope for future management of the bleeding joint disease.

Management of Dry Eye Disease

June 7th 2022

Dr Laura Periman, MD discusses biopsychosocial and economic impacts, as well as innovative treatment opportunities for patients with dry eye disease.

Improving Access to Appropriate Therapies in Atopic Dermatitis

May 20th 2022

Neal Bhatia, MD, discusses atopic dermatitis and the treatment process, as well as how to improve access to therapies for patients with this disease.

Paradigms in Insulin Use for Type 2 Diabetes

December 22nd 2021

Jennifer Brigitte Green, MD, discusses the management of type 2 diabetes for patients not currently controlled on oral antidiabetic medications.

Supporting Better Cancer Care Through Comprehensive Genomic Profiling (CGP)

December 10th 2021

Expert hematologist/oncologist David R. Gandara, MD, highlights the value comprehensive genomic profiling has in guiding therapeutic decisions.

Value-Based Decision-Making in Metastatic Breast Cancer

June 15th 2021

Recommendations for treating HER2-positive metastatic breast cancer with newer HER2-targeted treatment approaches and considerations regarding their adoption into clinical practice.

Advances in Biomarker-Driven Therapy for Advanced NSCLC

May 20th 2021

Paul K. Paik, MD, discusses the spectrum of targeted therapy in non-small cell lung cancer.

Challenges and Considerations in Treatment of Adult Spinal Muscular Atrophy

December 21st 2020

Key opinion leader discusses considerations for adult patients with spinal muscular atrophy (SMA) including disease burden, treatment evaluation, and the use of real-world evidence.